A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response

Carmichael, James; Cantwell, B. M. J.; Edwards, C. M.; Zussman, B. D.; Thompson, Sarah; Rapeport, Garth; Harris, Adrian L.

doi:10.1007/bf00254104

Cited by 152 publications

(59 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such patients may be those in whom the 5-HT3 receptor antagonists such as granisetron and ondansetron cause a complete or major inhibition of emesis (Carmichael et al, 1989;Marty et al, 1990). However, in the latter studies the 5-HT3 receptor antagonists were highly effective in at least 75% of patients, which does not correlate with the 40% of patients only in the present study showing a raised plasma 5-HT level.…”

contrasting

confidence: 81%

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine

Barnes¹,

Jin²,

Jones³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Nausea and vomiting induced by chemotherapy is a variable response related to the nature and intensity of treatment and patient susceptility. The mechanism whereby chemotherapy evokes nausea and vomiting is uncertain but recently, the ability of 5-HT3 receptor antagonists to antagonise chemotherapy induced emesis in animals (Costall et al., 1986;Miner & Sanger, 1986) and man (Cunningham et al., 1987; Leibundgut & Lancranjan, 1987;Kris et al., 1989)

show abstract

contrasting

confidence: 81%

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine

Barnes¹,

Jin²,

Jones³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…We have recently demonstrated that it is effective for preventing PONV in patients undergoing middle ear surgery as well as those undergoing gynaecological surgery [4,7]. The exact mechanism of granisetron in the prevention of PONV remains unclear, but it has been suggested that it may act on sites containing 5-HT3 receptors with demonstrated anti-emetic effects [8].…”

Section: R E T R a C T E Dmentioning

confidence: 99%

Retracted: Prophylactic anti‐emetic therapy with granisetron, droperidol and metoclopramide in female patients undergoing middle ear surgery

Fujii¹,

Toyooka²,

Tanaka³

1998

Anaesthesia

View full text Add to dashboard Cite

SummaryThe efficacy of granisetron, droperidol and metoclopramide for the prevention of postoperative nausea and vomiting in female patients undergoing middle ear surgery was compared. In a randomised, double-blind study, 180 patients received granisetron 40 mg.kg ¹1, droperidol 20 mg.kg ¹1 or metoclopramide 0.2 mg.kg ¹1 given intravenously immediately before induction of anaesthesia (n ¼ 60 for each). A standardised general anaesthetic technique was employed throughout. A complete response, defined as no postoperative nausea and vomiting and no need for another rescue anti-emetic, during the first 3 h after anaesthesia was achieved in 83%, 58% and 55% of patients who had received granisetron, droperidol and metoclopramide, respectively. The corresponding incidence during the next 21 h after anaesthesia was 85%, 54% and 47% (p < 0.05). No clinically important adverse effects were observed in any of the groups. We conclude that prophylactic therapy with granisetron is superior to droperidol or metoclopramide in the prevention of postoperative nausea and vomiting after middle ear surgery. Postoperative nausea and vomiting (PONV) are distressing and frequent adverse events after general anaesthesia and surgery [1] and patients who undergo middle ear surgery may be especially at risk of experiencing these problems. In the absence of any anti-emetic treatment, the incidence of PONV following middle ear surgery ranges from 62% to 80% [2,3]. We have recently demonstrated that granisetron, a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, reduces the incidence of PONV after middle ear surgery [4]. However, there have been no studies to compare its efficacy with commonly used and well-established anti-emetics in the prevention of PONV after middle ear surgery. This study was undertaken to assess the efficacy of granisetron, droperidol and metoclopramide, in a randomised, double-blind fashion, for the prevention of PONV in female patients undergoing middle ear surgery. MethodsApproval of our institutional review board and informed consent from patients were obtained. One hundred and eighty women, ASA physical status 1, aged 20-68 years and scheduled for middle ear surgery (tympanoplasty or mastoidectomy) were recruited into the study. Patients who had gastrointestinal diseases, those who had a history of motion sickness and/or previous PONV, those who were pregnant or menstruating, or those who had taken anti-emetics within 24 h before surgery were not studied.Patients were randomly assigned to one of three groups (n ¼ 60 for each) to receive a single dose of either granisetron 40 mg.kg

show abstract

“…2;3 Although the exact mechanism of granisetron in the prevention of postoperative emesis is not known, it has been suggested that it may act on sites containing 5-HT 3 receptors with demonstrated antiemetic effects. 8 It has been shown that effective doses of granisetron are between 40 and 80 lag. kg -I for the treatment of cancer theraphy-induced emesis.…”

Section: R E T R a C T E D A R T I C L Ementioning

confidence: 99%

Effective dose of granisetron for preventing postoperative emesis in children

1996

View full text Add to dashboard Cite

A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response

Cited by 152 publications

References 17 publications

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine

Retracted: Prophylactic anti‐emetic therapy with granisetron, droperidol and metoclopramide in female patients undergoing middle ear surgery

Effective dose of granisetron for preventing postoperative emesis in children

Contact Info

Product

Resources

About